Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

NCT04127578 is registered in ClinicalTrials.gov with Prevail Therapeutics as lead sponsor.

NCT NCT04127578
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04127578 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Lead sponsor
Prevail Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 3, 2020
Completion date
August 31, 2031
Enrollment
32 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease